Huntington Disease

Huntington disease (HD) is a progressive neurodegenerative disorder caused by a pathogenic expansion of CAG repeats in the HTT gene. It is inherited in an autosomal-dominant pattern. ^[1][2] The clinical identity of HD is a changing combination of movement disorder, cognitive impairment, psychiatric symptoms, and behavioral disturbance rather than a single required symptom. ^[2][6] Therefore, the absence of chorea does not exclude HD when other characteristic features are present.

The classic adult phenotype combines chorea , executive dysfunction, and psychiatric or behavioral illness. Chorea consists of brief and irregular involuntary movements that appear to flow unpredictably from one body region to another. Executive dysfunction refers to impaired planning, cognitive flexibility, organization, and inhibition; it can impair work and daily activities before global dementia develops. Psychiatric manifestations may include depression , anxiety, irritability, apathy, obsessive-compulsive behavior, or psychosis , and they may precede obvious motor signs. ^[2][6] This is why a patient with prominent behavioral or cognitive change can have clinically recognizable HD before chorea becomes conspicuous.

A person with an HTT expansion but no unequivocal disease manifestations has premanifest gene expansion. Premanifest status is not synonymous with complete biological quiescence because subtle changes may precede motor diagnosis by many years. ^[15] The term prodromal HD is useful for the intermediate clinical state in which small but reproducible cognitive, psychiatric, behavioral, or motor abnormalities are emerging without established manifest disease. Pyramidal signs may occur during this interval and can precede predicted motor onset by more than a decade. ^[11] These categories describe clinical expression rather than separate diseases.

Manifest HD begins when progressive abnormalities are sufficiently definite to be attributed to HD and are accompanied by functional consequences or a characteristic examination pattern. Chorea is common in adult-onset disease but is not obligatory. Other movement abnormalities include dystonia , parkinsonism , bradykinesia, impaired postural control, motor impersistence, tics, and abnormal saccades. ^[2] Cognitive and psychiatric features may dominate before or alongside the motor syndrome, so assessment must include behavior and executive function rather than relying on the movement examination alone. ^[6]

Juvenile-onset HD refers to onset at 20 years or younger. ^[4] The juvenile phenotype is often hypokinetic rather than choreic, with rigidity , bradykinesia, dystonia, gait dysfunction, dysarthria, or seizures; ataxia and developmental regression are especially relevant in very early childhood onset. ^[2][4] The historical term Westphal variant describes an early hypokinetic-rigid presentation, but it is not specific to juvenile disease and therefore should not replace the broader term juvenile-onset HD. ^[4]

Late-stage HD is defined clinically by severe loss of independence rather than by age alone. Patients may become bed-bound and require tube feeding and complete assistance with care. ^[4] Motor impairment then reflects the combined burden of chorea or dystonia, parkinsonism, gait apraxia, impaired balance, dysarthria, and dysphagia; cognitive and psychiatric disability further increases dependence. ^[2][4] The same disease therefore spans an initially subtle prodrome through a disabling multisystem neurodegenerative syndrome.

The causal mutation is an expanded tract of CAG trinucleotide repeats in exon 1 of the HTT gene on chromosome 4. Each CAG codon specifies glutamine, so the expansion produces huntingtin with an abnormally long polyglutamine tract called polyQ. ^[21] The repeat is unstable across cell divisions and generations, which means that the inherited allele can lengthen in offspring and can expand further within vulnerable neurons during life. ^[27]

Normal huntingtin is a widely expressed protein that supports intracellular transport and neuronal growth. ^[25] Mutant huntingtin instead alters protein structure and cellular responses to stress, so neurons must maintain transport, energy production, calcium balance, and protein clearance under progressively greater strain. ^[21] PolyQ-rich mutant fragments can misfold and oligomerize before forming visible intracellular aggregates. This is why aggregate burden is a marker of proteostatic failure rather than the sole explanation for neuronal death. ^[29]

CAG length strongly influences the timing of disease onset because longer repeats increase the toxic polyQ burden and promote somatic expansion. ^[27] Anticipation describes earlier onset or greater severity in successive generations, and paternal transmission receives special attention because the repeat is particularly prone to intergenerational expansion through the male germline. ^[27] Repeat length therefore provides a risk estimate for onset age rather than a calendar date because somatic expansion and genetic modifiers also alter the disease trajectory. ^[27] The repeat should be understood as a major determinant of timing, not as a deterministic predictor of an exact onset date. ^[40]

Several interacting mechanisms convert mutant huntingtin into neuronal injury. Transcriptional dysregulation changes the expression of genes that maintain neuronal identity and stress resistance, while epigenetic erosion causes vulnerable neurons to lose that identity prematurely. ^[23] Proteostasis also fails because the ubiquitin-proteasome system and the autophagy-lysosome pathway cannot adequately remove aggregate-prone huntingtin and its fragments. ^[31] Impaired transport of proteins and organelles then compounds this problem by limiting delivery of essential cargo and removal of damaged material. ^[21]

Mitochondrial and metabolic dysfunction reduce the energy available for axonal transport and synaptic signaling. Mutant huntingtin disrupts mitochondrial dynamics by favoring fission over fusion, which can impair ATP production and increase cellular stress. ^[32] Altered metabolism also affects microglia, where mitochondrial signaling promotes a pro-inflammatory state that can amplify neuronal injury. ^[33] These mechanisms explain why energy failure and inflammation reinforce one another rather than acting as separate toxic pathways.

Synapses fail before neurons are lost because mutant huntingtin disrupts neuronal excitability, calcium handling, and the molecular programs that maintain synaptic structure. ^[24] Corticostriatal communication becomes abnormal as transcriptional and synaptic programs change across both cortical and striatal projection neurons. ^[24] Excess glutamatergic drive can then produce excitotoxicity, meaning calcium-dependent injury caused by prolonged activation of glutamate receptors; toxin models reproduce this mechanism through NMDA-receptor overactivation. ^[22] The result is progressive loss of reliable information flow through motor, cognitive, and psychiatric circuits.

Neuroinflammation adds a non-neuronal component to this injury. Mutant huntingtin is expressed in microglia and astrocytes, so these cells can become reactive and sustain inflammatory signaling while astrocytic changes impair glutamate and ion homeostasis. ^[21] Microglial activation is detectable early and is associated with striatal neurodegeneration, which means inflammation may worsen neuronal vulnerability before extensive cell loss is evident. ^[22] Oligodendroglial dysfunction can further reduce axonal support and myelination, thereby weakening long-range connectivity. ^[34]

The most selective early neuronal loss occurs in striatal medium spiny neurons, also called striatal spiny projection neurons. Their vulnerability is linked to repeat-dependent transcriptional erosion and to the high physiological demands of integrating cortical input with basal-ganglia output. ^[23] Degeneration then extends to cortical pyramidal neurons and other subcortical structures, while white-matter abnormalities disrupt communication between regions. ^[27] Loss of inhibitory striatal GABAergic neurons distorts basal-ganglia motor pathway balance and contributes to chorea, whereas cortical involvement disrupts executive control and supports cognitive and psychiatric dysfunction. ^[22] Thus the anatomy explains why HD is a circuit disorder rather than an isolated lesion of the striatum.

Huntington disease is uncommon overall, but its frequency varies substantially across populations and regions. In studies from 2011–2022, pooled prevalence was 4.88 per 100,000 people and pooled incidence was 0.48 cases per 100,000 person-years.^[41] Across studies from 1985–2022, prevalence was higher in Europe and North America than in Asia and Africa, while incidence was also higher in Europe and North America than in Asia.^[41] These differences reflect ancestry-related repeat distributions and founder effects, but they also reflect underrecognition and unequal access to diagnostic services. Therefore, a low local prevalence must not be treated as evidence that HD does not occur in that population.^[41][42]

The highest reported frequencies occur in populations with largely European ancestry. Reported prevalence has ranged from 0.1 per 100,000 in Asian and African countries to 10 per 100,000 in European populations.^[42] Lower rates in many Asian and African populations are genuine epidemiologic observations, yet pathogenic HTT expansions have been identified in African and South Asian individuals.^[42] Clinicians should therefore ask about the phenotype and biological family relationships rather than exclude HD because a patient is from a population with a lower reported frequency.^[45][46]

An affected person who carries one expanded and one nonexpanded HTT allele has a 50% chance of transmitting the expanded allele to each child. This follows from the autosomal-dominant inheritance pattern because each parent contributes one of the two alleles at conception.^[44] The risk applies separately to every pregnancy, so the outcome in one child does not alter the probability for another child. A child who inherits the expanded allele may remain premanifest for years because age at onset and penetrance vary across repeat lengths and individuals.^[42]

A negative family history does not reduce the risk to zero when the patient has a compatible phenotype. A parent may have died before symptoms became recognizable, may have had psychiatric or cognitive manifestations attributed to another illness, or may have remained undiagnosed because late-onset HD is often overlooked. In a large European cohort, absent or unknown family history occurred in 31.2% of people with late-onset HD.^[52] De novo expansions also contribute to apparently sporadic disease, with one systematic review estimating that they account for 7.1% of new cases.^[41] Reduced family ascertainment can therefore conceal an inherited expansion even when no relative is known to have HD.^[42][45]

Family history, age, and symptoms alone cannot provide a reliable numerical estimate of an individual’s genetic risk. Family history may be incomplete, and the probability of inheriting an expanded allele depends primarily on the biological relationship to a carrier rather than on the number of relatives reported as affected.^[44][52] Age modifies the likelihood that a carrier has become clinically manifest, but it does not determine whether the allele was inherited because individuals with the same repeat length can develop HD decades apart.^[55] Symptoms may justify diagnostic evaluation, yet they cannot by themselves establish an expanded allele because HD phenocopies and other neurological disorders can produce overlapping manifestations.^[58] Use the pedigree to identify who may be at risk, then refer the person for genetic counseling rather than assigning reassurance or certainty from history alone.^[47][48]

Huntington disease (HD) evolves through several interacting domains rather than through chorea alone. Motor, cognitive, psychiatric, behavioral, and systemic changes may emerge at different times because disease burden is distributed across connected corticostriatal networks. Oculomotor abnormalities can precede unequivocal motor diagnosis, which means that slowed or poorly initiated saccades may be an early examination clue even when chorea is absent ^[67].

The motor phenotype is initially variable. Early chorea consists of brief, irregular movements that flow unpredictably from one body region to another, while dystonia produces sustained postures and twisting movements. Patients may also show impaired saccades, motor impersistence, dysarthria, or subtle gait and postural abnormalities before chorea becomes conspicuous ^[67]. Motor impersistence is tested by asking the patient to sustain tongue protrusion or a tight handgrip; an inability to maintain the posture supports impaired motor control rather than simple weakness. As the disease advances, chorea may coexist with dystonia and then with bradykinesia and rigidity, so a patient can become simultaneously overactive and slow. Gait dysfunction, impaired balance, and dysarthria then increase falls and communication problems ^[63].

Cognitive change often begins as reduced efficiency rather than obvious loss of knowledge. Slowed processing, impaired attention, executive dysfunction, and reduced working memory make multistep tasks difficult even when brief bedside orientation remains intact. Processing-speed changes have been reported up to 15 years before diagnosis, while visuospatial working-memory deficits can precede motor symptoms ^[66][64]. In practice, ask the patient to explain a plan, switch between rules, or hold information while performing another task; disproportionate difficulty suggests frontostriatal dysfunction. Later disease brings broader cognitive decline with impaired judgment and reduced ability to organize self-care, which increases dependence and vulnerability to exploitation ^[66].

Psychiatric and behavioral manifestations may precede motor recognition and may fluctuate independently of chorea. Depression, irritability, apathy, anxiety, obsessive-compulsive symptoms, impulsivity, psychosis, and suicidality reflect disruption of affective and motivational circuits rather than merely a reaction to disability ^[67]. Irritability and impulse-control difficulty can be especially prominent; gene expansion carriers have reported selective impulse-control problems even when total emotion-regulation scores do not differ from family controls ^[62]. Clinicians should therefore ask directly about suicidal thoughts, aggression, compulsive behaviors, hallucinations, delusions, and loss of judgment because patients may underreport these symptoms. In advanced disease, psychosis can coexist with medical complications and malnutrition, so behavioral deterioration requires assessment of both the brain syndrome and physical safety ^[61].

Systemic function declines as motor and bulbar impairment accumulate. Sleep disturbance, weight loss, dysphagia, dysarthria, and loss of independence may become more disabling than chorea itself; dysphagia is a frequent corticobulbar manifestation and can lead to aspiration and inadequate nutrition ^[63]. Observe eating when feasible, ask about coughing or prolonged meals, and track weight because swallowing inefficiency may be clinically important before the patient reports choking. Impaired activities of daily living reflect the combined effects of slowness, poor initiation, unsafe judgment, balance failure, and cognitive disorganization. Consequently, driving, medication management, cooking, finances, and supervision of dependents require repeated review rather than a one-time assessment ^[61].

Juvenile-onset HD has a distinctive pattern that can be missed if clinicians expect chorea. Rigidity, bradykinesia, dystonia, gait dysfunction, dysarthria, seizures, school decline, and behavioral change often appear before chorea, especially in very early disease; the initial presentation may therefore resemble a progressive hypokinetic or developmental disorder rather than adult-onset HD ^[66]. A child or adolescent with progressive loss of school skills plus new rigidity or seizures warrants examination for impaired saccades and a careful three-generation history. The absence of chorea does not make HD unlikely in this phenotype ^[66].

Pearl: Chorea is only one expression of HD. Progressive loss of coordinated movement, executive control, emotional regulation, communication, swallowing, and independence should prompt a multidomain examination even when chorea is absent ^[67].

Prodromal Huntington disease is clinically meaningful even when motor findings do not yet establish a diagnosis. The earliest changes often involve slowed processing speed and reduced benefit from repeated cognitive tasks rather than obvious memory loss. Subtle processing-speed abnormalities may appear up to 15 years before diagnosis, although routine testing can remain within the normal range. ^[66] Executive inefficiency then becomes more visible through difficulty shifting tasks, organizing work, managing competing demands, or learning from feedback. These changes matter because a person may still appear independent while taking longer to complete familiar responsibilities or making more errors at work.

Motor examination can reveal abnormalities before the patient reports a movement problem. Slowed or poorly initiated saccades are especially useful because eye-movement abnormalities often precede clinical motor diagnosis. ^[67] Look for reduced saccade velocity, impaired smooth pursuit, and difficulty initiating a saccade, then compare performance across visits rather than treating one borderline finding as diagnostic. ^[67] Early gait or postural irregularity and impaired motor persistence may add support when they are reproducible. This is why collateral history and longitudinal examination are more informative than a single impression of whether chorea is present.

Psychiatric and behavioral symptoms may be the first change recognized by the family. Apathy reduces initiation and sustained effort, whereas irritability may produce disproportionate anger or conflict; either can be mistaken for a personality problem. Premanifest carriers can report selective difficulty controlling impulses, and the degree of emotional dysregulation varies widely between individuals. ^[62] Depression and suicidal thinking require direct questioning because they may fluctuate independently of motor severity and can create immediate safety risk. Sleep disruption also belongs in the prodromal assessment because poor sleep, insomnia, daytime sleepiness, fragmented sleep, and circadian disturbance have been described before motor onset. ^[79]

Functional inefficiency marks the transition from subtle disease to clearly consequential disease. Ask whether the person can still manage finances, medications, driving, work pace, household tasks, and appointments without correction or supervision. A normal score on a brief cognitive screen does not exclude early executive disability because real-world organization places greater demands on frontostriatal networks. Reassess function with collateral information because the patient may compensate for months or years before a caregiver recognizes decline. ^[66]

The usual trajectory is progressive but not uniform. Early manifest disease may preserve independent living while chorea, dystonia, slowed movement, dysarthria, executive dysfunction, or psychiatric symptoms gradually interfere with work and complex daily activities. ^[67] As postural control and judgment worsen, falls become more likely; recurrent falls are associated with balance impairment and may also reflect chorea or executive dysfunction. ^[81] Later disease brings increasing dependence for personal care, transfers, continence, and medication management, while rigidity and bradykinesia may become more prominent than chorea. This sequence is a clinical tendency rather than a timetable because genetic burden, age at onset, psychiatric illness, nutrition, comorbidity, and available support alter the course. ^[72]

Bulbar dysfunction often becomes more disabling than the movement disorder itself. Dysarthria progressively reduces speech intelligibility, while dysphagia causes prolonged meals, weight loss, dehydration, malnutrition, and aspiration risk. Corticobulbar symptoms are frequent manifestations of HD, and rapid progression can make structured assessment difficult. ^[63] Review eating efficiency, coughing during meals, wet voice, recurrent chest infection, and unintentional weight loss at every stage. Loss of safe oral intake may eventually require a feeding discussion, but the decision must reflect prognosis, patient preferences, aspiration burden, and caregiver capacity.

Advanced HD is defined by loss of function rather than by a particular age or duration of illness. The person may become unable to walk safely, communicate reliably, control continence, or complete any activity of daily living without continuous assistance. Severe rigidity, dystonia, falls, dysarthria, dysphagia, incontinence, weight loss, and immobility can coexist, so care must address comfort and prevention of avoidable complications rather than focus only on chorea. Weight loss and cachexia reduce autonomy and increase morbidity and mortality risk, which makes nutrition and energy balance central to functional care. ^[84] When communication is minimal or absent, establish the person’s preferences early and use familiar caregivers to interpret distress, pain, hunger, fear, and fatigue.

The following phase framework supports counseling without implying that every patient passes through each phase at the same speed. A phase is defined by the dominant functional consequence, not by a single symptom.

Several features are associated with earlier onset or faster progression, but none precisely predicts one person’s course. A larger expanded CAG tract generally increases genetic disease burden and is associated with earlier onset, while higher burden also tends to accompany faster cognitive and functional change. ^[66][72] Juvenile-onset disease often follows a different hypokinetic-rigid pattern and may progress rapidly; expansions above 55 CAG repeats are more likely to be associated with juvenile or atypical phenotypes. ^[66] Depression or suicidality, weight loss, and early functional decline signal greater clinical vulnerability because they threaten safety, nutrition, or independence even when motor impairment is modest. ^[62][84][85] Use these features to intensify monitoring and planning rather than to assign an exact age of onset or a fixed survival estimate. Prognosis is therefore best communicated as a range that is revised with serial motor, cognitive, psychiatric, nutritional, swallowing, and functional observations. ^[72]

A suspected manifest Huntington disease (HD) is confirmed by demonstrating a pathogenic CAG-repeat expansion in HTT in a patient whose progressive syndrome is clinically compatible with HD. The molecular result establishes the cause, while the examination establishes whether the person is manifest rather than merely carrying an expansion. First-tier testing usually measures the HTT repeat by fragment analysis; atypical or discordant results may require a laboratory method that characterizes the repeat sequence more completely. ^[2][39]

Clinical confirmation

Begin with a three-generation pedigree that records movement symptoms, dementia, psychiatric illness, suicide, early institutionalization, unexplained accidents, and causes and ages of death. Ask separately about each parent, sibling, child, aunt, uncle, and grandparent because relatives may have been mislabeled as having depression or may have died before motor disease became recognizable. A negative family history therefore lowers confidence only modestly and must not replace molecular testing. ^[76]

Establish the earliest reproducible change and its tempo. Ask when chorea, clumsiness, falls, dysarthria, slowed thinking, irritability, apathy, depression, impulsivity, psychosis, or loss of work efficiency began. Obtain collateral history because executive dysfunction can impair medication use, finances, driving, appointments, and household tasks before the patient reports clear disability. Review all prescribed drugs, over-the-counter products, supplements, recreational substances, and toxin exposures, then compare symptom onset with each exposure and any dose change. ^[2][76]

Perform a movement-disorders examination rather than relying on chorea alone. Look for irregular, flowing movements and assess motor impersistence by asking the patient to sustain tongue protrusion or a handgrip. Examine saccade initiation and velocity, smooth pursuit, eye movements, dystonia, rigidity, bradykinesia, myoclonus, tics, dysarthria, gait, postural stability, pyramidal signs, and coordination. Saccadic slowing favors HD, whereas prominent ataxia or central positional nystagmus should increase suspicion for a spinocerebellar ataxia. ^[2]

Assess cognition with attention, processing speed, executive function, working memory, language, and visuospatial tasks. Ask directly about depression, anxiety, irritability, apathy, obsessive-compulsive symptoms, impulsivity, hallucinations, delusions, and suicidal thinking. Functional assessment must include work or school performance, medication management, finances, driving, cooking, shopping, personal care, swallowing, and the need for supervision. A clinical diagnosis of manifest HD requires abnormalities that are progressive and attributable to HD; when standardized motor ratings are used, a Diagnostic Confidence Level of 4 corresponds to at least 99% confidence that the motor abnormalities are due to HD. ^[92]

Neuroimaging and laboratory assessment

Obtain brain MRI when the diagnosis is uncertain, the presentation is atypical, or a structural lesion must be excluded. HD commonly produces bilateral caudate-head atrophy and may later involve the putamen and wider cortical and subcortical structures. CT can demonstrate marked caudate atrophy or calcification when MRI is unavailable. These findings support the diagnosis but do not establish it because atrophy is not specific and early imaging may be nondiagnostic. Imaging should therefore answer two questions: does the pattern support a degenerative striatal process, and is there another explanation such as stroke, tumor, hydrocephalus, demyelination, or basal-ganglia calcification? ^[2][76]

Use laboratory testing selectively rather than ordering an undirected panel for every patient. A practical initial screen includes blood count with smear, electrolytes, renal and liver tests, thyroid function, serum copper, ceruloplasmin, 24-hour urinary copper, autoimmune markers, and vasculitis markers when the history or examination supports those causes. Add antiphospholipid antibodies for thrombosis, pregnancy morbidity, livedo, or stroke; cerebrospinal-fluid studies for inflammatory or infectious features; and CT of the chest, abdomen, and pelvis when a paraneoplastic syndrome is plausible. ^[76]

A negative HTT expansion does not end the evaluation. Approximately 1% of people with a typical HD phenotype lack a pathogenic HTT expansion, so persistent suspicion requires systematic assessment for acquired disease followed by phenotype-directed genetic testing. ^[2]

When HTT testing is negative and acquired causes have been excluded, order a repeat-expansion panel that includes C9orf72, SCA17, DRPLA, and HDL2 when the phenotype permits. HDL2 caused by a JPH3 expansion can be nearly indistinguishable from HD, while SCA17 more often adds ataxia, tremor, or distinctive ocular-motor findings. If targeted testing is unrevealing, proceed to exome or genome sequencing because structural variants and repeat expansions may be missed by a limited panel. ^[2][76]

Pearl: Confirm HD molecularly, but confirm manifest disease clinically. A normal scan or absent pedigree does not exclude HD, and a caudate-predominant scan does not prove it; a negative HTT result should redirect the workup toward treatable acquired causes and genetic phenocopies. ^[2][76]

HTT testing answers different clinical questions, so the laboratory request must state whether the purpose is diagnosis, prediction, or reproductive planning. In a symptomatic person with a progressive syndrome compatible with Huntington disease , test an appropriate blood sample with a validated HTT CAG-repeat assay because a pathogenic expansion establishes the molecular cause. A negative result does not end evaluation when the phenotype remains persuasive because phenocopies and technical limitations remain possible. ^[76]

Interpreting the HTT CAG-repeat result

Interpret the repeat number as a category rather than as an exact forecast. The usual reporting framework is shown below; laboratories may describe boundaries slightly differently when repeat structure or assay resolution is uncertain.

A full-penetrance result in a symptomatic person supports the diagnosis, whereas the same result in an asymptomatic person establishes genetic status but not clinical disease onset. A reduced-penetrance result requires especially careful counseling because the result may not resolve whether a parent’s symptoms were caused by HD or whether a child will develop disease. Repeat length correlates with onset at a population level, but current prediction models do not provide sufficiently accurate individual onset or progression estimates for routine clinical use. ^[80]

Repeat sizing is not a direct measurement of the expansion in every vulnerable neuron. Somatic instability causes repeat distributions to differ among tissues, and blood-based fragment analysis may therefore underestimate the repeat size that has accumulated in brain neurons. ^[99] Tissue-specific and age-dependent expansion has also been detected in blood and other tissues, which means that a single blood result cannot describe the full biological range within an individual. ^[27] Loss-of-interruption variants can make current assays underestimate the effective repeat length, especially in the reduced-penetrance range. ^[88] Request specialist laboratory review when the result is borderline, the phenotype and repeat size disagree, or the report indicates unusual repeat structure.

Do not tell a carrier that symptoms will begin at a particular age. Use the repeat length to explain a broad group-level tendency, then emphasize that genetic modifiers, repeat structure, somatic expansion, sex, family variation, and clinical features alter the individual course. A person can therefore use the result for planning without treating it as a timetable. ^[80]

Predictive testing and counseling

Predictive testing is an elective adult decision, not a routine blood test. Follow the Huntington Disease Society of America and International Huntington Association principles by arranging informed consent and pretest counseling before collecting the sample. Counseling must explain the possible results, the limits of age-of-onset prediction, effects on relatives, confidentiality, employment and insurance concerns, reproductive choices, and the option to defer or decline testing. The HDSA protocol was developed specifically for predictive testing, and current guidance recognizes that genomic testing and health-record policies can expose results before the clinical disclosure visit. ^[97]

Assess the person’s neurological and psychological state before testing because an apparently asymptomatic applicant may already have depression, impulsivity, cognitive difficulty, or emerging motor signs. Ask directly about suicidal thoughts, previous attempts, access to lethal means, substance use, recent losses, domestic safety, and available support. Do not proceed until an acute psychiatric crisis is treated and a safe follow-up plan is established. The HDSA protocol requires in-person result disclosure because of increased suicidality risk in the HD population. ^[98]

Offer an independent support person rather than making a partner or at-risk relative responsible for the applicant’s care. Arrange post-test contact before the sample is drawn, and provide a scheduled result visit with immediate access to genetic counseling, neurology, mental-health care, and crisis services. A positive result can bring relief from uncertainty but can also produce grief, fatalism, stigma, survivor guilt, or altered decisions about relationships, work, finances, and parenthood. ^[95] Genetic discrimination and stigma are reported concerns for people with HD and inherited risk, so discuss privacy and carefully limit result disclosure. ^[100]

Do not release a predictive result through an unsupervised portal or disclose it to relatives without the tested person’s permission. If a healthcare system releases results automatically, warn the patient beforehand and document a plan for rapid clinician contact because immediate release can lead to misinterpretation and may increase concern about suicidality. ^[98]

Family communication and uncertain family history

An HTT result has consequences for biological relatives, but the tested person retains control over personal disclosure except where local law creates a specific duty. Encourage the person to share a clear family letter that explains the result, inheritance risk, and referral pathway without pressuring relatives to test. A relative’s decision not to know is valid. Avoid testing a relative secretly or using another person’s result as a substitute for that relative’s own consent.

An uninformative family history does not make HD unlikely enough to avoid testing when the clinical syndrome is compatible. Early parental death, psychiatric mislabeling, adoption, nonpaternity, reduced penetrance, late onset, and nondisclosure can conceal the transmission path. ^[76] If the affected relative was never tested, explain that a negative result in the patient may be less informative than testing the clinically affected person first. When the pedigree cannot establish whether an intervening parent carried the expansion, report the patient’s residual risk qualitatively and refer for formal pedigree-based counseling rather than offering false reassurance.

Minors and reproductive decisions

Do not perform predictive testing in an asymptomatic minor solely to resolve future adult-onset risk. The child cannot yet make an informed adult decision, and the result usually offers no immediate medical benefit. Test a minor when symptoms suggest juvenile-onset HD or when a result will change current medical care; involve a pediatric neurologist, clinical geneticist, and psychological professional.

Offer reproductive counseling before conception to an adult carrier or at-risk person. Each pregnancy has an independent 50% chance of inheriting the expansion from a heterozygous carrier parent. ^[80] Discuss the full range of options without directing the person toward or away from parenthood: natural conception with no fetal testing, prenatal diagnosis, donor gametes, adoption, and preimplantation genetic testing for monogenic disorders (PGT-M). Personal attitudes toward testing may differ from attitudes toward testing embryos, so explore both decisions separately and protect reproductive autonomy. ^[95]

Prenatal diagnosis can use chorionic-villus sampling or amniocentesis to test fetal DNA for the familial HTT expansion. Obtain a documented familial pathogenic expansion before offering targeted fetal testing whenever possible, because testing without a known familial result may be difficult to interpret. Counsel in advance about whether the parents want to know fetal status, the possibility of pregnancy termination according to local law and personal values, and the need for rapid psychological support after either result.

PGT-M tests embryos created through in vitro fertilization before transfer, allowing transfer of embryos that do not carry the familial expansion. It avoids an established pregnancy termination for a known fetal result, but it involves ovarian stimulation, procedures, laboratory uncertainty, possible failure to obtain a transferable embryo, and ethical questions about embryo selection. Reproductive counseling must therefore present PGT-M as an option rather than a recommendation. ^[95]

Huntington disease severity is multidimensional, so no single score can represent the patient’s disease burden. Use the Unified Huntington’s Disease Rating Scale (UHDRS) as a structured baseline and repeat it at clinically meaningful intervals. The UHDRS combines motor examination with functional, cognitive, and behavioral assessment, which prevents chorea from becoming a misleading proxy for overall disability. ^[108]

The UHDRS Total Motor Score (TMS) rates the severity of observed motor abnormalities. Its items capture chorea and dystonia as well as bradykinetic, oculomotor, dysarthric, gait, and postural abnormalities. A higher TMS generally indicates greater motor impairment, but the score is not a direct measure of independence because falls or swallowing failure may worsen while the motor examination changes little. TMS is therefore useful for tracking motor progression and for research endpoints, while functional measures determine what the motor change means in daily life. The TMS is also used with the motor examination to support the clinician’s confidence that observed abnormalities are attributable to HD. ^[108][92]

Interpret the chorea and dystonia subscales separately when the phenotype changes over time. A patient may have less chorea as rigidity and bradykinesia emerge, yet become less mobile and more dependent. The total motor score can therefore remain stable or change modestly despite clinically meaningful deterioration in gait, balance, speech, or transfers. Document the dominant motor problem rather than treating a lower chorea score as improvement in overall disease.

The UHDRS Functional Assessment asks about the patient’s ability to manage work or usual role, finances, domestic responsibilities, and activities of daily living. These questions identify loss of complex independence that a brief office examination may miss. ^[107] The UHDRS Independence Scale complements this assessment by describing how much supervision or assistance the patient requires. Obtain collateral information because impaired awareness can occur even when functional capacity is still intact. In one study, anosognosia was present in 22% of participants with a TFC score of 13. ^[107]

The UHDRS cognitive section samples processing speed and executive abilities. Add a Montreal Cognitive Assessment (MoCA) when a brief cognitive screen is needed, or use a more detailed neuropsychological battery when work, driving, finances, or medication management are changing. A normal brief screen does not exclude executive inefficiency, so compare test results with collateral reports and real-world performance. Functionally meaningful cognitive change depends on disease stage and follow-up duration rather than one universal cutoff. ^[105]

The Total Functional Capacity (TFC) scale is the central functional anchor for clinical staging. It rates occupation, finances, domestic chores, activities of daily living, and the level of care required. ^[107] Use the TFC to communicate practical independence and to assign Shoulson–Fahn stage, but treat the stage as a summary of current function rather than a fixed forecast.

For Shoulson–Fahn staging, use the TFC range as the principal determinant: stage I corresponds to TFC 11–13, stage II to TFC 7–10, stage III to TFC 3–6, stage IV to TFC 1–2, and stage V to TFC 0. A TFC of 13 indicates preserved measured capacity but does not guarantee safe independent performance because anosognosia and subtle executive impairment may already be present. ^[107] Record the actual TFC with the stage so that a change within a stage is not mistaken for no progression.

The Clinical Global Impression provides a clinician’s integrated judgment of overall severity or interval change. Use it after reviewing motor findings, function, cognition, psychiatric symptoms, and complications rather than allowing chorea to dominate the rating. The Problem Behaviors Assessment short form is useful when irritability, apathy, depression, impulsivity, psychosis, or suicidality is clinically relevant. Its distributions contain many zero scores in early disease and its factor structure changes across stages, so a low score does not exclude important behavioral change. ^[104]

Use the MoCA for a brief cognitive screen when time is limited, then escalate to formal neuropsychological testing if executive dysfunction affects employment, driving, finances, medication use, or safety. Ask the patient and an informant about real-world performance because patient-reported impairment may underestimate objective disability. The relationship between self-report and performance-based cognitive measures is not sufficiently strong to justify relying on self-report alone. ^[106][107]

Use the Hospital Anxiety and Depression Scale (HADS) when anxiety or depression requires a brief symptom measure. A structured psychiatric interview is preferable when symptoms are severe, psychosis is suspected, behavior is rapidly changing, or suicide risk is possible. Ask directly about suicidal thoughts, intent, planning, access to means, and protective supports. Record the answer and obtain collateral history because suicidality can be clinically important even when motor scores are modest.

Estimate prognosis from serial trajectories rather than isolated labels. Repeat the same instruments under similar conditions and examine the slope of TMS, TFC, cognition, behavior, and safety outcomes. A change becomes clinically meaningful when it is reproducible and accompanied by altered everyday function; cognitive thresholds for meaningful decline differ by disease stage and observation interval. ^[105] Use a range rather than an exact date because progression is heterogeneous and prognostic models require sufficient accuracy and clinically useful uncertainty before routine implementation. ^[80]

Falls, nutrition, swallowing, suicidality, and caregiver burden can worsen prognosis independently of the TMS. Ask about falls since the last visit and assess fear of falling even when the patient’s chorea appears unchanged; the HD-specific FALL-HD screen assesses stability, fear, and fall history. ^[108] Review weight, meal duration, coughing, wet voice, recurrent chest infections, and hydration because dysphagia can produce malnutrition or aspiration without a proportional motor-score increase. Swallowing symptoms occur across the HD-ISS spectrum and become more severe with advancing stage. ^[117]

Assess caregiver burden directly by asking how much supervision is required for medications, finances, meals, transport, behavior, and nighttime care. A stable TFC may conceal rising caregiver strain when the family is compensating for cognitive or behavioral disability. Treat a new suicidal thought, repeated fall, rapid weight loss, or choking episode as a prognostic and safety signal that warrants urgent reassessment rather than waiting for the next scheduled rating visit.

Pearl: The most useful severity statement combines the current TFC and TMS with cognitive, psychiatric, swallowing, nutrition, falls, and caregiver findings, then compares each domain with its prior trajectory.

Treat motor symptoms according to their functional cost rather than the examination score alone. Chorea merits treatment when it causes falls, injury, exhaustion, pain, loss of feeding or dressing efficiency, or unacceptable social disability. Ask the patient and care partner to define one or two treatment goals, then reassess gait, transfers, alertness, mood, swallowing, and independence because suppressing chorea can expose bradykinesia or rigidity. Expert consensus recommends individualized titration and regular feedback from patients and care partners. ^[120]

Chorea

VMAT2 inhibitors are the principal drug treatment for disabling chorea because they reduce presynaptic dopamine packaging and release. Randomized evidence shows that tetrabenazine, deutetrabenazine, and valbenazine reduce chorea scores compared with placebo, but no trial has established that one agent is universally superior. ^[121] Choose the drug by dosing convenience, psychiatric vulnerability, sedation, parkinsonism, cardiac risk, and access rather than by chorea score alone.

Deutetrabenazine requires slow escalation because the therapeutic window is limited by sedation, akathisia, parkinsonism, and mood effects. Tetrabenazine is also effective, but comparative evidence associates it with more adverse events and poorer tolerability than deutetrabenazine or valbenazine. ^[121] A retrospective series found that doses above 48 mg/day did not improve the median chorea score and were associated with more extrapyramidal symptoms, so exceeding the labeled maximum should not be routine. ^[128]

Tetrabenazine requires the strongest psychiatric caution. A boxed warning concerns depression and suicidality in Huntington disease; do not use it in actively suicidal patients or in untreated major depression, and obtain collateral monitoring when treatment is considered. The warning does not mean that every patient with past depression is ineligible, but it does require documented baseline mood assessment and repeated direct questioning about suicidal thoughts. Tetrabenazine was most often associated with mood disorders and sedation in a one-year randomized study. ^[126]

Review drug interactions before prescribing any VMAT2 inhibitor. Strong CYP2D6 inhibitors can raise exposure to tetrabenazine and deutetrabenazine, so apply the lower maximum doses and avoid combining interacting agents when possible. ^[124] Check for additive sedation from benzodiazepines, opioids, sedating antihistamines, and antipsychotics. Obtain an ECG when there is congenital or acquired QT risk, electrolyte disturbance, structural heart disease, or concurrent QT-prolonging medication; reassess the regimen if the QT interval becomes clinically concerning.

Antipsychotics are preferable to VMAT2 inhibitors when chorea occurs with psychosis, aggression, or severe behavioral disturbance because they can suppress dopaminergic motor activation while treating the behavioral syndrome. Atypical antipsychotics generally control psychosis in reported HD cases, but sedation and extrapyramidal symptoms are common. ^[129] Olanzapine is a reasonable choice when irritability and chorea coexist, although rigidity may increase and weight or lipid abnormalities may develop. ^[126] Use risperidone or aripiprazole when a more activating profile is desired, and use quetiapine when sedation or lower extrapyramidal burden is clinically useful. Start one agent at a low dose and avoid stacking antidopaminergic drugs unless specialist review shows a clear benefit because sedation, cognitive slowing, rigidity, and falls can compound functional loss. ^[124]

Dystonia, rigidity, bradykinesia, and gait dysfunction

Rehabilitation is the foundation for hypokinetic and postural motor problems because medication has limited and unpredictable effects on balance, coordination, and motor planning. Prescribe physical therapy for gait training, balance recovery, transfers, strengthening, cueing, and falls prevention. Add occupational therapy for dressing, bathing, workarounds, and assistive devices. A moderate-intensity inpatient program using walking, resistance training, cycling, and water activities improved walking capacity and selected executive measures even though the primary motor score did not differ between groups. ^[131]

Treat focal dystonia with targeted botulinum toxin when a defined muscle pattern causes pain, contracture, impaired gait, or difficulty with hygiene. Use oral baclofen or tizanidine only when generalized spasticity or painful sustained contraction justifies their sedating effects. Consider levodopa for severe rigidity and bradykinesia, particularly in juvenile-onset or hypokinetic-predominant disease, but use a cautious trial because dopaminergic treatment may worsen chorea, hallucinations, or behavioral activation. Evidence for dopaminergic and antispasticity treatment in HD remains limited, so judge continuation by measurable improvement in transfers, walking, pain, or care burden rather than by dose escalation alone.

Reassess the motor phenotype whenever chorea improves. A lower chorea score may reflect emerging rigidity or bradykinesia rather than recovery, so document dystonia, gait speed, postural stability, falls, transfers, and upper-limb function separately. Reduce or stop the suppressive drug when sedation, parkinsonism, falls, or loss of initiation outweighs chorea reduction.

Pearl: The best motor regimen is the one that improves safe function without exchanging chorea for sedation, depression, rigidity, or falls.

Assess psychiatric and cognitive symptoms at every visit because they may fluctuate independently of motor severity and may be underreported. Ask the patient and care partner about mood, anxiety, obsessive thoughts, irritability, aggression, impulsivity, apathy, manic symptoms, psychosis, sleep, cognition, medication adherence, driving, finances, and suicidal thinking. Use structured measures such as the PHQ-9 for depression, GAD-7 for anxiety, the Problem Behaviors Assessment–short form for behavioral symptoms, and the MoCA for cognitive screening, but interpret scores alongside collateral history and functional change ^[85]. A coordinated clinic model can stabilize depressive and anxiety trajectories, although observational data do not prove that the model itself caused improvement ^[85].

Treat depressive and anxiety syndromes with psychotherapy adapted to executive impairment and with an SSRI such as sertraline, escitalopram, or fluoxetine when tolerated. An SNRI such as venlafaxine or duloxetine is an alternative when anxiety, pain, or inadequate SSRI response supports that choice. Start low, increase gradually, and reassess sleep, activation, akathisia, falls, sexual adverse effects, hyponatremia, and suicidal thinking after each dose change. Depression is not always a psychological reaction to HD because frontostriatal dysfunction can produce intrinsic affective symptoms, so treatment should address both psychosocial stressors and neurologic disease ^[85].

Manage anxiety and obsessive-compulsive symptoms with predictable routines, behavioral therapy, stimulus reduction, and caregiver coaching before adding medication. Use an SSRI or SNRI when symptoms are persistent or disabling, then monitor for increased activation, insomnia, impulsivity, or akathisia. A sudden increase in rituals or perseveration may reflect executive dysfunction rather than a primary obsessive-compulsive disorder, so obtain collateral examples and assess the effect on eating, hygiene, finances, and safety.

Irritability, aggression, and impulsivity require a trigger-based plan before medication escalation. Reduce noise and confrontation, offer one-step choices, preserve a regular daily schedule, remove access to weapons and other hazards, and train caregivers to disengage early when arousal rises. Treat pain, constipation, urinary symptoms, infection, sleep loss, medication changes, depression, mania, and psychosis because each can amplify aggression. If behavior remains dangerous or severely disabling, use an antipsychotic such as risperidone, olanzapine, quetiapine, or aripiprazole; consider valproate or carbamazepine when mood instability, impulsive aggression, or comorbid seizure risk supports a mood-stabilizer strategy ^[85].

Choose psychotropics by the adverse effect most likely to worsen function. Monitor sedation and orthostasis because they increase falls and caregiver burden; monitor akathisia because it can resemble agitation and intensify suicidal distress; monitor weight, glucose, and lipids with antipsychotics because metabolic effects accumulate; and monitor rigidity, bradykinesia, dysarthria, swallowing, and falls because dopamine blockade can worsen parkinsonism. Consider overdose toxicity and medication access when prescribing for a person with suicidal thinking, and use supervised dispensing when necessary. Reassess after each change rather than escalating several drugs simultaneously.

Treat psychosis when hallucinations, delusions, or paranoia cause distress, impaired care, aggression, or loss of reality testing. First exclude delirium, infection, substance exposure, medication effects, severe sleep deprivation, and an affective episode. Start one antipsychotic at a low dose and titrate cautiously because excessive dopamine blockade can worsen motor and cognitive function; quetiapine or olanzapine may be useful when insomnia or agitation accompanies psychosis, whereas aripiprazole may be preferred when sedation or metabolic risk is especially concerning. Obtain urgent psychiatric or emergency assessment when psychosis produces command hallucinations, violent intent, inability to maintain basic safety, or refusal of essential care.

Apathy requires activation rather than indiscriminate sedation. Distinguish apathy from depression by asking about sadness, guilt, hopelessness, anhedonia, emotional reactivity, and desire for activities; apathy may progress independently of depression ^[113]. Use scheduled activity, external prompts, graded exercise, meaningful roles, visual calendars, and caregiver-initiated routines. Consider an antidepressant only when depressive symptoms are present, and reserve a cautious stimulant trial for selected patients after reviewing sleep, impulsivity, psychosis, cardiac risk, and appetite; evidence for stimulants in HD remains limited.

Mania or marked behavioral activation requires assessment for antidepressant-induced activation, medication effects, sleep deprivation, substance use, and delirium. Use a mood stabilizer such as valproate or carbamazepine when clinically indicated, or an antipsychotic when mania includes psychosis, severe agitation, or dangerous impulsivity. Escalate to urgent psychiatric care when the patient has little or no sleep, escalating risk-taking, aggression, psychosis, inability to cooperate with care, or rapidly worsening judgment.

Cognitive management should prioritize compensation because no routine cognitive drug has established disease-modifying benefit in HD. Use simplified instructions, written checklists, alarms, pill organizers supervised by a care partner, reduced multitasking, consistent object placement, and occupational-therapy strategies for work and household tasks. Review driving, finances, medication management, online transactions, and vulnerability to exploitation because brief screening can miss executive disability. Cholinesterase inhibitors such as donepezil have not succeeded as disease-modifying treatment, and evidence for memantine, stimulants, and cognitive rehabilitation remains limited or preliminary ^[85][144]. Therefore, use these approaches only as individualized specialist trials with a defined target and stop rule rather than as routine cognitive pharmacotherapy.

Address insomnia and circadian disruption with a fixed wake time, morning daylight exposure, daytime activity, limited naps, reduced evening light, and a quiet predictable bedtime routine. Review caffeine, alcohol, evening medications, pain, nocturia, depression, anxiety, mania, akathisia, and sleep-disordered breathing because treating the driver is safer than adding sedatives. Assess daytime somnolence and falls before prescribing any sedating drug, and reduce unnecessary sedatives when alertness or mobility worsens. Sleep disturbance is common across premanifest and manifest HD, while evidence for effective pharmacologic or behavioral treatment remains scarce and inconclusive ^[79].

Ask directly about suicidal thoughts at every psychiatric review and after major losses, diagnostic disclosures, medication changes, worsening depression, increased irritability, or functional decline. Clarify passive death wishes, active ideation, intent, plan, access to means, preparatory behavior, prior attempts, psychosis, intoxication, impulsivity, and protective supports; ask the care partner separately when possible. Depression, hopelessness, anxiety, aggression, and irritability are associated with suicidal ideation in HD, which is particularly elevated during premanifest and early disease stages ^[140].

Treat active suicidal intent, a feasible plan, preparatory behavior, inability to collaborate on safety, severe intoxication, command hallucinations, or absence of reliable supervision as an emergency: do not leave the patient alone, restrict lethal means, arrange same-day psychiatric or emergency evaluation, and involve the care partner with consent or under applicable safety exceptions. For lower but persistent risk, create a written safety plan, provide crisis contacts, increase visit or telephone frequency, supervise medication access, and document who will monitor the patient overnight. Do not infer safety from a later reduction in reported ideation because reduced communication capacity in advanced HD can mimic improvement ^[140].

Integrated care is particularly useful when psychiatric symptoms, cognition, motor disability, and caregiver strain interact. Coordinate neurology, psychiatry, psychology, social work, occupational therapy, and care-partner support so that one clinician does not worsen another domain while treating a different one ^[85].

Pearl: In HD, the safest psychiatric prescription is usually the smallest effective regimen paired with structured routines, collateral monitoring, and a clearly documented escalation plan.

Huntington disease requires rehabilitation that is revisited as motor, cognitive, behavioral, bulbar, and functional abilities change. A coordinated team prevents one intervention from worsening another because treatment that reduces chorea may increase rigidity, sedation, falls, or swallowing difficulty. Multidisciplinary care commonly includes neurology, psychiatry, physical therapy , occupational therapy , speech-language pathology , neuropsychology , nursing, dietetics, social work, and palliative care . ^[85]

Physical therapy should assess gait, postural reactions, transfers, endurance, fatigue, and the home environment. Prescribe regular, supervised exercise that combines strength, aerobic activity, flexibility, task practice, and balance training. Use simple routines with external cues because executive dysfunction and impaired motor planning reduce the ability to learn complex sequences. Practice turning, rising from a chair, bed mobility, and safe transfers with the care partner. Falls are frequent in HD and often occur indoors, so balance assessment must lead to concrete changes in footwear, lighting, floor surfaces, furniture, and supervision. ^[81]

Use occupational therapy to preserve independence in dressing, feeding, bathing, toileting, medication administration, and household tasks. The therapist should provide adaptive equipment such as shower chairs, grab rails, raised toilet seats, transfer aids, weighted or lidded utensils, cups with controlled flow, and clothing with simplified fasteners. Equipment must be tested during the actual task because chorea, dystonia, bradykinesia, impulsivity, and visuospatial or executive impairment can make an apparently helpful device unsafe. Review occupational safety early: modify duties, reduce multitasking, establish written routines, and involve the employer with consent when errors, slowed responses, falls, or behavioral symptoms threaten safety.

Driving decisions require a structured assessment rather than a diagnosis-based prohibition. Review crashes, near misses, navigation errors, traffic violations, medication sedation, vision, reaction time, judgment, and collateral reports. Refer to a formal driving evaluation when concern exists, and recommend driving cessation when the person cannot reliably control the vehicle or follow a safety plan. Work decisions should follow the same principle: preserve meaningful activity when possible, but change duties or stop hazardous work when executive impairment, impulsivity, falls, or slowed responses create unacceptable risk. Neuropsychology is useful when cognitive findings affect driving, employment, finances, medication management, or consent because brief screening can miss executive disability. ^[85]

Speech-language pathology should assess intelligibility, speech rate, respiratory support, phonation, oral-motor control, cognition, and the person’s ability to communicate urgent needs. Introduce communication supports before speech becomes unreliable. These may include gesture and facial-expression training, alphabet or topic boards, written keywords, picture systems, smartphone or tablet applications, amplified speech, and eye-gaze or other augmentative systems. Train communication partners to ask one question at a time, allow extra response time, confirm the intended message, and avoid correcting every articulation error. Remote speech assessment is promising, but it remains an adjunct to direct clinical examination rather than a replacement for it. ^[152]

Assess swallowing at baseline and repeatedly after weight loss, prolonged meals, coughing, throat clearing, wet voice, recurrent respiratory illness, fatigue while eating, or a change in medication or motor state. A bedside assessment by speech-language pathology should examine alertness, posture, oral preparation, chewing, bolus control, voice quality, and meal duration. Refer for instrumental assessment such as videofluoroscopic swallow study or fiberoptic endoscopic evaluation of swallowing when bedside findings are unclear, symptoms progress, silent airway invasion is suspected, or the safest diet cannot be determined clinically. ^[63]

Modify texture only after assessing the person’s specific swallowing impairment. Use appropriate food consistency, controlled sip size, upright positioning, slow pacing, reduced distractions, and supervised feeding when needed. Avoid a diet change that reduces intake without a compensatory plan because texture modification can worsen dehydration, weight loss, and enjoyment of meals. Train every person who feeds the patient, including paid staff, and document the required posture, pace, utensils, supervision, and signs that require stopping the meal. A home-based corticobulbar program was associated with exploratory improvements in selected speech and swallowing outcomes, so structured practice may be worthwhile when the patient and care partner can perform it safely. ^[63]

Nursing should coordinate the daily safety plan and check whether recommendations are being followed at home or in residential care. Nurses can monitor falls, skin integrity, continence, sleep, medication administration, choking signs, drooling, fatigue, caregiver strain, and changes in behavior. Manage drooling by correcting posture, improving lip closure and swallowing frequency, reviewing medicines that increase salivation, and referring for targeted treatment such as anticholinergic therapy or botulinum toxin when appropriate. Balance secretion reduction against thick saliva, constipation, urinary retention, blurred vision, confusion, and worsening swallowing.

Dietetics should measure weight at each clinical review when feasible, review the trajectory rather than a single value, and assess intake, meal duration, food access, swallowing restrictions, mood, apathy, executive dysfunction, involuntary-movement burden, and gastrointestinal symptoms. Weight loss in HD can occur despite appetite because dysphagia and increased energy expenditure combine with disease-related metabolic demands. ^[151] Provide energy-dense meals and snacks with adequate protein, fortify familiar foods, use oral supplements when tolerated, and involve the patient in selecting culturally familiar foods. High-energy diets and supplements are widely used but may be poorly tolerated long term, so reassess benefit, taste, constipation, satiety, cost, and caregiver workload. ^[150]

Discuss enteral feeding before a crisis. Consider it when oral intake no longer maintains hydration or nutrition, meals are persistently exhausting, swallowing is unsafe despite individualized strategies, or feeding requires more supervision than the care setting can provide. The decision must include the patient’s preferences, previously expressed wishes, capacity, prognosis, expected burdens, and the goals of the family. A feeding tube is not a default response to weight loss and does not remove the need for oral comfort feeding when that remains safe and desired. If the patient lacks capacity, use the legally recognized surrogate process and the person’s known values rather than treating family preference alone as consent.

Palliative care should be introduced early and can work alongside disease-directed treatment. It helps clarify goals, manage distressing symptoms, support communication, prepare for residential or home care, and guide decisions about hospitalization, feeding, and future loss of independence. Early palliative involvement is particularly useful when advanced HD produces psychosis, malnutrition, repeated hospitalizations, or difficult medication decisions. ^[61] Advance directives should specify the preferred decision-maker, acceptable levels of hospitalization, feeding preferences, emergency treatment goals, and the desired place of care. Revisit them after major functional decline or a new swallowing, psychiatric, or safety problem.

Neuropsychology and the treating clinician should assess decision-specific capacity rather than assume that a diagnosis or low cognitive score eliminates autonomy. Evaluate whether the person can understand relevant information, appreciate consequences, reason between options, and communicate a stable choice. Assess capacity separately for consent to treatment, driving, finances, residence, and feeding because abilities may differ across decisions. When capacity is impaired, use supported decision-making whenever possible by simplifying information, allowing extra time, using trusted communication partners, and documenting the person’s preferences. Seek guardianship or another formal substitute decision-making arrangement only when less restrictive supports cannot protect the person from serious harm, and follow local law.

Family-centered care must include the person with HD and caregivers in every care conference. Nursing and social work should teach the family how to cue movement, supervise meals, respond to irritability, remove hazards, administer medicines, and recognize urgent changes in swallowing, falls, mood, or safety. Social work should arrange respite, benefits, transportation, home nursing, equipment, day programs, caregiver training, and residential placement when home care is no longer safe or sustainable. Caregivers often experience physical, financial, and psychological strain across several generations, so assess caregiver burden directly rather than waiting for a crisis. ^[101] Offer culturally appropriate support through trained interpreters, respect for food practices and family roles, and discussion of spiritual or community resources. Do not assume that the person who speaks most loudly is the decision-maker.

Pearl: Reassess function, swallowing, nutrition, communication, capacity, and caregiver capacity together because a change in one domain often changes the safety plan for all the others.

Aspiration is the dominant preventable medical threat in advanced Huntington disease . Dysphagia reduces airway protection, while weak cough prevents clearance of aspirated material. Aspiration pneumonia is a leading cause of hospital admission and the primary cause of death in HD. ^[157] Treat a new cough, fever, hypoxemia, tachypnea, wet voice, or reduced alertness as possible aspiration even when the patient does not report choking, because silent aspiration is common in progressive bulbar dysfunction. ^[157]

Complication and emergency checklist

Falls are frequent across HD stages and usually arise from intrinsic balance or cognitive-motor problems rather than an isolated gait parameter. In one study, 72% of falls occurred indoors, and recurrent fallers received higher neuroleptic doses. ^[81] Therefore, inspect the home, supervise transfers, and treat every fall with a medication and orthostatic review rather than simply prescribing a walking aid. A fall with anticoagulant use, loss of consciousness, repeated vomiting, new headache, seizure, or focal deficit requires emergency assessment for head injury .

Acute emergencies

Treat choking as an airway emergency. Call emergency services, remove food only when visible, and use choking maneuvers appropriate to the patient’s age and consciousness. After airway clearance, assess for hypoxemia, laryngeal injury, aspiration, and rib injury. Do not resume eating until swallowing safety has been reassessed.

Treat new confusion as delirium until proven otherwise rather than labeling it psychiatric deterioration. Check oxygenation, glucose, temperature, hydration, pain, urinary retention, constipation, recent medication changes, and infection. Delirium with fever, rigidity, autonomic instability, or marked reduction in consciousness requires hospital evaluation because infection, drug toxicity, neuroleptic malignant syndrome , and nonconvulsive seizures may be clinically indistinguishable at the bedside.

A fever with respiratory symptoms requires prompt examination for aspiration pneumonia. Obtain oxygen saturation and chest imaging when indicated, give oxygen for hypoxemia, obtain cultures in severe illness, and start empiric antibiotics according to local pneumonia guidance. Avoid sedating cough suppressants when airway clearance is poor. Weak cough is clinically actionable: voluntary peak cough flow below 300 L/min indicates cough dysfunction, while values below 160 L/min represent severe impairment for which mechanical insufflation-exsufflation may be considered. ^[157]

Juvenile-onset HD deserves a lower threshold for epilepsy assessment because seizures occur in approximately 30% to 50% of juvenile cases, compared with approximately 1% in adults. ^[148] During a convulsion, protect the head, place the patient laterally when possible, time the seizure, check glucose, and do not restrain or place objects in the mouth. Treat a seizure lasting 5 minutes or longer, or recurrent seizures without recovery, as status epilepticus using the local emergency benzodiazepine protocol and urgent intravenous antiseizure treatment. Obtain electroencephalography when staring, fluctuating responsiveness, or abnormal movements could represent nonconvulsive seizures; long-term video EEG can help distinguish seizures from HD movements. ^[148] Refer juvenile patients with seizures to an epileptologist and review antiseizure drug adverse effects because sedation can worsen swallowing, mobility, and participation.

Acute behavioral danger requires safety before diagnostic refinement. Use a quiet room, one speaker, short sentences, and adequate personal space. Remove weapons and other hazards, involve a trusted caregiver, and search for delirium, infection, pain, sleep deprivation, intoxication, withdrawal, or a recent drug change. Psychosis commonly presents with delusions or hallucinations, and antipsychotic treatment can cause sedation or extrapyramidal symptoms. ^[129] If medication is required, use one antipsychotic at a low dose and monitor rigidity, bradykinesia, orthostasis, swallowing, temperature, and falls. Do not escalate dopamine blockade reflexively when the patient becomes rigid or less mobile.

Suicidal thoughts require direct questioning even when motor disease is mild because suicidal ideation is particularly prominent in premanifest and early HD. ^[140] Ask about intent, method, access, preparation, substance use, psychosis, and the availability of supervision. Active intent or a feasible plan requires immediate means restriction, continuous supervision, and same-day emergency psychiatric assessment. Do not leave a high-risk patient alone or send them home with unsupervised medications.

Late-stage medical care

Late-stage care is defined by dependence and complication burden rather than by a particular age. Bed dependence, contractures, rigidity, loss of speech, dysphagia, recurrent aspiration, incontinence, and inability to transfer safely require a coordinated nursing and palliative plan. Use positioning, gentle range-of-motion, splints when tolerated, pressure relief, continence care, secretion management, and communication supports. Preserve eye gaze, gestures, communication boards, or augmentative devices when speech becomes unreliable.

Recurrent aspiration should trigger a goals-of-care discussion rather than an automatic sequence of hospital admissions. Continue safe comfort feeding when the patient values oral intake, even when it does not provide full nutrition. Discuss gastrostomy separately from aspiration prevention because available studies in HD are few and have inconclusive outcomes; gastrostomy may also increase care needs. ^[158] Offer enteral feeding only when its expected benefits match the patient’s preferences and decision-making plan.

Refer to hospice when progressive dependence is accompanied by recurrent aspiration, severe malnutrition, repeated infections, bed dependence, or a shift toward comfort as the principal goal. Early end-of-life planning can reduce later conflict, but discussions must be patient-centered and involve the right people at the right time. ^[147] Document preferences about hospitalization, antibiotics, intravenous fluids, tube feeding, resuscitation, restraints, and treatment of seizures while the patient can participate.

Comfort-focused care means treating dyspnea, pain, anxiety, agitation, secretions, constipation, and thirst without pursuing burdensome interventions that conflict with the patient’s goals. Avoid restraints, repeated invasive investigations, intensive care, or feeding procedures when they are unlikely to restore a valued function or when the advance plan declines them. Familiar caregivers, structured routines, emotional support, nutritional care, and palliative principles are associated with higher-quality care in specialist HD settings. ^[159]

Pearl: In advanced HD, a new cough, fever, fall, confusion, rigidity, seizure, or suicidal statement is a medical emergency until a reversible cause has been excluded; the safest plan is the one that protects airway, brain, and dignity while honoring the patient’s goals.

No disease-modifying therapy has been approved to halt or slow Huntington disease . ^[70] Investigational care therefore belongs in an ethically reviewed clinical trial and must never replace symptomatic treatment, rehabilitation, psychiatric safety planning, or advance care planning. ^[70]

The leading strategy is to reduce production of toxic huntingtin rather than treat each downstream consequence. Antisense oligonucleotide approaches use short nucleic-acid sequences to alter HTT RNA, while RNA interference uses small RNAs to recruit cellular RNA-silencing machinery. Tominersen is an example of an HTT-lowering antisense strategy, and HTT1a-directed approaches seek the aberrantly processed transcript that produces a particularly toxic huntingtin fragment. ^{[161] [27]} The central safety problem is selectivity: nonselective lowering may also remove normal huntingtin, which supports axonal transport, autophagy, and synaptic plasticity. ^[78] Therefore, a useful treatment must lower the harmful species sufficiently while preserving enough normal protein for neuronal maintenance.

Allele-selective silencing attempts to suppress the mutant HTT allele while sparing the normal allele. It may use an allele-specific single-nucleotide variant or the expanded repeat itself as the distinguishing sequence. ^[88] This approach could improve the therapeutic window, but it depends on adequate variant coverage and reliable delivery to vulnerable brain regions. RNA-targeting small molecules offer a related goal through oral or systemically administered compounds that modify RNA processing or translation. These approaches remain investigational because target engagement in the human brain, durability of effect, and off-target RNA effects must be demonstrated before clinical benefit can be inferred.

Gene-suppression and gene-editing approaches seek a more durable reduction of mutant HTT expression. Viral delivery may provide prolonged expression of a silencing construct, whereas CRISPR -based editing could in principle disable or rewrite the pathogenic allele. ^[21] Permanent or long-lasting interventions require especially strict assessment of off-target editing, immune reactions, regional distribution, reversibility, and effects on normal HTT. These risks are consequential because loss of normal HTT in adult striatal neurons reduced neuronal excitability and produced neuroinflammation in a mouse model. ^[78]

A second therapeutic direction is to increase neuronal resilience without directly lowering HTT. Candidate mechanisms include mitochondrial support, modulation of integrated stress responses, improved proteostasis, reduced neuroinflammation, and preservation of synaptic function. ^[21] In a cellular model, mitochondrial pyruvate-carrier inhibition preserved ATP and reduced an integrated-stress-response signal, but it did not reduce soluble or aggregated mutant huntingtin. ^[162] That result illustrates why a favorable molecular readout does not establish disease modification. Ganglioside-based strategies such as GM1 have shown anti-inflammatory and proteostasis effects in HD models, but these findings remain preclinical. ^[165] Supplements and repurposed drugs should therefore be discussed as research hypotheses rather than recommended disease-modifying treatment; current evidence is insufficient to support clinical use of resveratrol in HD. ^[168]

Trial timing matters because biological degeneration can precede overt clinical signs by many years. The HD-ISS classifies Stage 0 by pathogenic HTT carriage, Stage 1 by caudate or putamen atrophy, Stage 2 by clinical signs, and Stage 3 by loss of everyday function. ^[70] Early intervention may offer the best chance to prevent irreversible neuronal loss, but early trials also need endpoints that change measurably before disability becomes obvious. ^[70] A treatment that changes a biomarker without preserving function therefore has not yet shown meaningful benefit.

Cerebrospinal fluid mutant huntingtin is a pharmacodynamic biomarker because a fall can demonstrate target engagement. It is not automatically a validated surrogate for slower progression. Neurofilament light chain is a marker of axonal injury and may help assess biological disease activity, but its relationship to an individual patient’s functional future requires longitudinal validation. Somatic-repeat measures may refine biological stratification because somatic instability in vulnerable neurons contributes to HD pathogenesis. ^[99] Loss-of-interruption variants also matter because current diagnostic assays may underestimate effective CAG length and distort trial interpretation. ^[88]

The UHDRS remains a clinical outcome framework because it samples motor, cognitive, behavioral, and functional domains. TFC is the principal functional anchor for independence and is more directly meaningful to patients than a laboratory signal alone. ^[70] Digital motor measures and automated speech analysis may reduce rater burden and capture change between clinic visits. A machine-learning speech index correlated with cUHDRS, TMS, SDMT, and caudate and putamen volumes, but its proposed value for remote monitoring remains exploratory rather than equivalent to validation as a disease-modifying endpoint. ^[82]

MRI measures of caudate and putamen volume are biologically informative because atrophy can precede clinical signs. ^[70] Functional connectivity and effective-connectivity measures may reveal circuit disruption across HD-ISS stages, but their sensitivity, reproducibility, and resistance to motion artifacts still require confirmation. ^[70] Progression models using CAG length, age, neuroimaging, clinical scores, and longitudinal slopes can enrich trials and balance treatment groups. They cannot yet provide sufficiently accurate individual onset or progression predictions for routine clinical practice. ^[80]

Mixed or negative trial results do not prove that HTT lowering is futile. They may reflect inadequate target engagement, treatment that began after substantial neuronal loss, an unsuitable dose, insufficient distribution through the brain, or toxicity from excessive or nonselective lowering. ^[78] A biomarker can also move in the desired direction without translating into improved TFC, cognition, swallowing, falls, or quality of life. This is why future trials should prespecify exposure and target-engagement measures, use clinically meaningful longitudinal outcomes, and monitor safety across motor, psychiatric, cognitive, and bulbar domains.

Refer patients who are interested to an HD-experienced neurologist or research center that can explain eligibility, randomization, placebo probability, invasive procedures, uncertain benefit, withdrawal rights, contraception or reproductive implications, and data confidentiality. Confirm that the study has appropriate institutional review, independent consent procedures, psychiatric risk management, and a plan for communicating incidental findings. Participation can advance knowledge, but enrollment is not treatment and must not be presented as a promise of benefit.

Pearl: Treat investigational biomarkers as evidence about biology until they demonstrate reliable prediction of patient-centered outcomes; preserve UHDRS and TFC as clinical anchors while using CSF, imaging, and digital measures to explain how a therapy may—or may not—be working.